Of the children who received dupilumab, 8.9% developed ocular surface complications and 3.4% developed periocular involvement ...

Patients with chronic rhinosinusitis with nasal polyps and uncontrolled asthma experienced greater improvements in lung ...

Among adults with COPD and type 2 inflammation, having a history of cardiovascular or metabolic disease did not change ...

Extended dosing of dupilumab in patients with AD has similar efficacy as standard dosing, with no significant affect seen on ocular adverse events.

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window BOSTON -- ...

C HICAGO -- Adverse event risks varied across biologics used by asthma patients, an analysis of data submitted to the FDA ...

Health Canada has approved Dupixent® (dupilumab injection) as an add-on maintenance treatment in adult patients with chronic ...

Asthma clinical remission among patients taking dupilumab is most likely to occur in those with increased baseline BEC and FeNO levels.

Compared with placebo, dupilumab treatment resulted in statistically significant and meaningful symptom improvements in adults and adolescents with eosinophilic esophagitis (EoE), according to ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window PHOENIX -- ...

VANCOUVER, Canada — New evidence from the phase 3 EoE KIDS trial supports the safety and efficacy of dupilumab (Dupixent) treatment for children aged 1-11 years with eosinophilic esophagitis (EoE).

Dupilumab (Dupixent) relieves signs and symptoms of eosinophilic esophagitis (EoE) for up to 52 weeks, researchers say. Few side effects, other than injection pain, emerged in the year-long phase 3 ...